Mesenchymal Stem Cells Prevent Acute Rejection and Prolong Graft Function in Pancreatic Islet Transplantation
- 1 June 2010
- journal article
- research article
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 12 (6) , 435-446
Abstract
Background: Pancreatic islet transplantation is a promising cell-based therapy for type 1 diabetes (insulin-dependent diabetes mellitus), a disease triggered by the immune response against autoantigens of beta-cells. However, the recurrence of immune response after transplantation and the diabetogenic and growth-stunting side effects of immunosuppressants are major challenges to the application of islet transplantation. Mesenchymal stem cells (MSCs) have recently been reported to modulate the immune response in allogeneic transplantation. Methods: The ability of MSCs, either syngeneic or allogeneic to recipients, to prevent acute rejection and improve glycemic control was investigated in rats with diabetes given a marginal mass of pancreatic islets through the portal vein. Results: Reduced glucose levels and low-grade rejections were observed up to 15 days after transplantation upon triple-dose administration of MSCs, indicating that MSCs prolong graft function by preventing acute rejection. The efficacy of MSCs was associated with a reduction of pro-inflammatory cytokines and was independent of the administration route. Efficacy was similar for MSCs whether syngeneic or allogeneic to recipients and comparable to that of immunosuppressive therapy. Conclusions: The results show that MSCs modulate the immune response through a down-regulation of pro-inflammatory cytokines, suggesting that MSCs may prevent acute rejection and improve graft function in portal vein pancreatic islet transplantation.Keywords
This publication has 53 references indexed in Scilit:
- Transplantation: current developments and future directions; The future of clinical islet transplantation as a cure for diabetesFrontiers in Bioscience-Landmark, 2008
- Islet transplantation for type 1 diabetes—where should we go?Nature Clinical Practice Endocrinology & Metabolism, 2007
- Single-Donor, Marginal-Dose Islet Transplantation in Patients With Type 1 DiabetesJAMA, 2005
- Clinical islet transplantation: advances and immunological challengesNature Reviews Immunology, 2004
- Percutaneous transhepatic catheterization of the portal vein: A combined CT- and fluoroscopy-guided techniqueCardioVascular and Interventional Radiology, 1999
- Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients.Diabetes, 1999
- Progressive Islet Graft Failure Occurs Significantly Earlier in Autoantibody-Positive Than in Autoantibody-Negative IDDM Recipients of Intrahepatic Islet AllograftsDiabetes, 1997
- ISLET CELL ANTIBODIES AND GLUTAMIC ACID DECARBOXYLASE ANTIBODIES IN PATIENTS WITH INSULIN-DEPENDENT DIABETES MELLITUS UNDERGOING KIDNEY AND ISLET-AFTER-KIDNEY TRANSPLANTATION1Transplantation, 1996
- Islet Cell Transplantation in Diabetes Mellitus — from Bench to BedsideExperimental and Clinical Endocrinology & Diabetes, 1995
- Evolution of kidney, pancreas, and islet transplantation for patients with diabetes at the University of MinnesotaThe American Journal of Surgery, 1993